UBS Group’s Vaccinex, Inc. Common Stock VCNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-3,402
| Closed | -$11.6K | – | 10651 |
|
|
2024
Q3 | $11.6K | Buy |
+3,402
| New | +$19.1K | ﹤0.01% | 7671 |
|
|
2024
Q2 | – | Sell |
-101
| Closed | -$748 | – | 10290 |
|
|
2024
Q1 | $748 | Buy |
101
+77
| +321% | +$668 | ﹤0.01% | 8379 |
|
|
2023
Q4 | $225 | Sell |
24
-877
| -97% | -$10.4K | ﹤0.01% | 8792 |
|
|
2023
Q3 | $14.2K | Buy |
+901
| New | +$45.8K | ﹤0.01% | 6962 |
|
|
2023
Q2 | – | Sell |
-78
| Closed | -$6.49K | – | 8637 |
|
|
2023
Q1 | $6.53K | Buy |
78
+68
| +680% | +$7.47K | ﹤0.01% | 7910 |
|
|
2022
Q4 | $1.38K | Buy |
+10
| New | +$1.24K | ﹤0.01% | 9884 |
|
|
2022
Q1 | – | Sell |
-1
| Closed | – | – | 11069 |
|
|
2021
Q4 | $0 | Sell |
1
-26
| -96% | -$9.38K | ﹤0.01% | 10856 |
|
|
2021
Q3 | $12K | Buy |
27
+9
| +50% | +$4.49K | ﹤0.01% | 7801 |
|
|
2021
Q2 | $10K | Sell |
18
-119
| -87% | -$62.9K | ﹤0.01% | 8068 |
|
|
2021
Q1 | $86K | Buy |
+137
| New | +$88.1K | ﹤0.01% | 6082 |
|
|
2020
Q3 | – | Sell |
-9
| Closed | -$7K | – | 8501 |
|
|
2020
Q2 | $7K | Buy |
9
+7
| +350% | +$5.46K | ﹤0.01% | 7240 |
|
|
2020
Q1 | $1K | Sell |
2
-8
| -80% | -$9.07K | ﹤0.01% | 7823 |
|
|
2019
Q4 | $11K | Sell |
10
-1
| -9% | -$1.13K | ﹤0.01% | 7253 |
|
|
2019
Q3 | $17K | Buy |
+11
| New | +$12.4K | ﹤0.01% | 6841 |
|
|
2019
Q2 | – | Sell |
-11
| Closed | -$12K | – | 8223 |
|
|
2019
Q1 | $12K | Buy |
11
+1
| +10% | +$960 | ﹤0.01% | 6702 |
|
|
2018
Q4 | $7K | Buy |
10
+7
| +233% | +$8.55K | ﹤0.01% | 7429 |
|
|
2018
Q3 | $5K | Buy |
+3
| New | +$6.19K | ﹤0.01% | 7516 |
|
Other funds holding VCNX
UBS Group's VCNX Position: Q4 2024 in Review
UBS Group sold out of Vaccinex, Inc. Common Stock (VCNX) in Q4 2024, closing a stake of 3,402 shares — an estimated $11.6K sold.
UBS Group first reported a position in VCNX in Q3 2018 and held it in 17 quarters. The position peaked at $86K in Q1 2021. 1 fund tracked by Wall St. Rank holds VCNX as of Q4 2024.
- UBS Group reported no remaining Vaccinex, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- UBS Group sold 3,402 Vaccinex, Inc. Common Stock shares in Q4 2024, an estimated $11.6K.
- UBS Group first reported a position in Vaccinex, Inc. Common Stock in Q3 2018 and held it in 17 quarters.
- UBS Group's Vaccinex, Inc. Common Stock position peaked at $86K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q4 2024.
Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.